福元医药：达格列净片获药品注册证书

Core Viewpoint - Fuyuan Pharmaceutical (601089) has received a drug registration certificate for Dapagliflozin tablets from the National Medical Products Administration, which is expected to enhance the company's product line and market competitiveness [1] Company Summary - Fuyuan Pharmaceutical's wholly-owned subsidiary, Fuyuan Pharma, received the drug registration certificate for Dapagliflozin tablets, suitable for adult patients with type 2 diabetes, in 5mg and 10mg specifications [1] - The company invested a total of RMB 6.07 million in the research and development of this drug as of the announcement date [1] Market Summary - The sales revenue of Dapagliflozin tablets in China's three major terminal markets reached approximately RMB 5.222 billion in 2023 [1] - The approval of the drug registration certificate is anticipated to enrich the company's product offerings and improve its competitive position in the market [1]